期刊文献+

纳米微载体介导的低氧诱导因子-1圈套寡核苷酸对小鼠HepG_2细胞血管内皮生长因子的作用

The Effect of Hypoxia-inducible Factor-1 Decoy Oligodeoxynucleotide Mediated by Nano Micro Carrier on Vascular Endothelial Growth Factor in HepG2 Cells of Mice
下载PDF
导出
摘要 目的:以低氧诱导因子(HIF)-1为靶点,观察HIF-1转录因子圈套寡核苷酸(HIF-1 decoy ODN))对小鼠HepG2细胞内血管内皮生长因子(VEGF)的作用,在分子水平为肝细胞癌干预靶点提供实验依据。方法:用ELISA法测定小鼠HepG2细胞内VEGF浓度。用逆转录-聚合酶链式反应测定小鼠HepG2细胞内VEGFmRNA。结果:HIF-1 decoy ODN在体外能有效抑制HIF-1活性。DecoyODN治疗后小鼠HepG2细胞内VEGF表达明显下降,而变异的decoyODN无效果。结论:纳米微载体介导的HIF-1 decoy ODN能下调HepG2细胞的VEGF水平。 Objective: To investigate the effect of hypoxia-inducible factor-l(HIF-1)decoy oligodeoxynucleotide(ODN) mediated by nano micro cartier on vascular endothelial growth factor(VEGF) in HepG2 cells of mice. Methods: ELISA was used to detect the contents of VEGF and RT-PCR to detect the mRNA of VEGF. Results: The HIF-1 decoy ODN could effectively inhibit the activity of VEGF in vitro. After treatment with decoy ODN, the expression of VEGF significandy decreased. Conclusion: The HW -1 decoy ODN mediated by nano micro carrier cart decrease the VEGF in HepG2 cells of mice.
出处 《汕头大学医学院学报》 2011年第3期156-158,168,共4页 Journal of Shantou University Medical College
基金 广东省医学科研基金资助项目(A2008443)
关键词 纳米载体 低氧诱导因子-1 血管内皮生长因子 圈套寡核苷酸 小鼠 nano carrier, hypoxia-inducible factor-1, vascular endothelial growth factor, decoyoligodeoxynucleotide,mice
  • 相关文献

参考文献6

  • 1DUDEK A Z, PAWLAK W Z, KIRSTEIN M N. Molecular targets in the inhibition of angiogenesis[ J ]. Expert in Their Targets, 2003, 7(4) : 527 - 541.
  • 2DAMERT A, MACHEIN M, BBEIER G, et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms [ J ]. Cancer Res, 1997, 57(17) : 3860- 3864.
  • 3VAUPEL P, KALLINOWSKI F, OKUNIEFF P. Blood flow , oxygen and nutrient supply, and metabolic human tumors: a review[J]. Cancer Res, 1989, 49(23): 6449-6465.
  • 4MOON E J, JEONG C H, JEONG J W, et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-in- ducible factor-1alpha[J]. FASEB J, 2004, 18(2): 382- 384.
  • 5LEE J K, HONG Y J, HAN C J, et al. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? [ J]. Int J Oncol, 2000, 17: 149-152.
  • 6JELKMAN W. Pitfalls in the measurement of circulating vascu- lar endothelial growth factor[J]. Clin Chem, 2001, 47:617 - 623.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部